Download Table of Contents - Molecular Cancer Therapeutics

Contents
Molecular
Cancer
Therapeutics
The Cancer Drug Development Journal: From Concept to Clinic
March 2011 Volume 10 Number 3
437
Highlights of This Issue 373
SPOTLIGHT ON MOLECULAR PROFILING
375
Global microRNA Analysis of the
NCI-60 Cancer Cell Panel
Jeffim N. Kuznetsov, Guy J. Leclerc,
Gilles M. Leclerc, and Julio C. Barredo
Rolf Søkilde, Bogumil Kaczkowski,
Agnieszka Podolska, Susanna Cirera,
Jan Gorodkin, Søren Møller, and
Thomas Litman
448
BRAFV600E: Implications for
Carcinogenesis and Molecular
Therapy
461
Emma R. Cantwell-Dorris, John J. O’Leary,
and Orla M. Sheils
395
Pushing the Envelope in the mTOR
Pathway: The Second Generation of
Inhibitors
472
sFLT01: A Novel Fusion Protein with
Antiangiogenic Activity
481
Rebecca G. Bagley, Leslie Kurtzberg,
William Weber, Tri-Hung Nguyen,
Stephanie Roth, Roy Krumbholz, Min Yao,
Brenda Richards, Mindy Zhang, Peter Pechan,
Steve Schmid, Abraham Scaria,
Johanne Kaplan, and Beverly A. Teicher
Studies on Mechanism of Action of
Anticancer Peptides by Modulation of
Hydrophobicity Within a Defined
Structural Framework
PRECLINICAL DEVELOPMENT
495
Lipoprotein Lipase Links Dietary Fat
to Solid Tumor Cell Proliferation
Increased Sensitivity to Thiopurines
in Methylthioadenosine
Phosphorylase–Deleted Cancers
Sally A. Coulthard, Christopher P.F. Redfern,
Svante Vikingsson, Malin Lindqvist-Appell,
Karin Skoglund, Ingrid Jakobsen-Falk,
Andrew G. Hall, Gordon A. Taylor, and
Linda A. Hogarth
Nancy B. Kuemmerle, Evelien Rysman,
Portia S. Lombardo, Alison J. Flanagan,
Brea C. Lipe, Wendy A. Wells, Jason R. Pettus,
Heather M. Froehlich, Vincent A. Memoli,
Peter M. Morganelli, Johannes V. Swinnen,
Luika A. Timmerman, Leila Chaychi,
Catherine J. Fricano, Burton L. Eisenberg,
William B. Coleman, and William B. Kinlaw
Integrating Targets, Technologies, and Treatments
JAK1 Activates STAT3 Activity in
Non-Small–Cell Lung Cancer Cells
and IL-6 Neutralizing Antibodies Can
Suppress JAK1-STAT3 Signaling
Lanxi Song, Bhupendra Rawal,
Jeffrey A. Nemeth, and Eric B. Haura
Yi-bing Huang, Xiao-fei Wang,
Hong-ye Wang, Yu Liu, and Yuxin Chen
427
Comprehensive Evaluation of the
Contribution of X Chromosome Genes
to Platinum Sensitivity
Eric R. Gamazon, Hae Kyung Im,
Peter H. O’Donnell, Dana Ziliak, Amy L. Stark,
Nancy J. Cox, M. Eileen Dolan, and
Rong Stephanie Huang
THERAPEUTIC DISCOVERY
416
Targeting Sarcoplasmic/Endoplasmic
Reticulum Ca2+-ATPase 2 by
Curcumin Induces ER StressAssociated Apoptosis for Treating
Human Liposarcoma
Lu Wang, Lingxian Wang, Ran Song, Yan Shen,
Yang Sun, Yanhong Gu, Yongqian Shu, and
Qiang Xu
Eduardo Vilar, Jose Perez-Garcia, and
Josep Tabernero
404
ORAI1-mediated Calcium Influx in
Lactation and in Breast Cancer
Damara McAndrew, Desma M. Grice,
Amelia A. Peters, Felicity M. Davis,
Teneale Stewart, Michelle Rice,
Chanel E. Smart, Melissa A. Brown,
Paraic A. Kenny, Sarah J. Roberts-Thomson,
and Gregory R. Monteith
REVIEWS
385
AMPK and Akt Determine Apoptotic
Cell Death Following Perturbations of
One-carbon Metabolism by
Regulating ER Stress in Acute
Lymphoblastic Leukemia
iii
www.aacrjournals.org
Downloaded from mct.aacrjournals.org on June 15, 2017. © 2011 American Association for Cancer Research.
505
Connexin-26 Is a Key Factor
Mediating Gemcitabine Bystander
Effect
550
Laura Garcia-Rodrı́guez, Sandra Perez-Torras,
Meritxell Carrió, Anna Cascante,
Ignacio Garcı́a-Ribas, Adela Mazo, and
Cristina Fillat
518
Liping Xu, Shuping Yin, and
Kaladhar B. Reddy
Synergistic Effects of Foretinib with
HER-Targeted Agents in MET and
HER1- or HER2-Coactivated Tumor
Cells
MOLECULAR MEDICINE IN PRACTICE
558
Li Liu, Hong Shi, Yuan Liu, Amber Anderson,
John Peterson, James Greger,
Anne-Marie Martin, and Tona M. Gilmer
531
PIK3CA Mutations in Patients with
Advanced Cancers Treated with
PI3K/AKT/mTOR Axis Inhibitors
Filip Janku, Apostolia M. Tsimberidou,
Ignacio Garrido-Laguna, Xuemei Wang,
Rajyalakshmi Luthra, David S. Hong,
Aung Naing, Gerald S. Falchook,
John W. Moroney, Sarina A. Piha-Paul,
Jennifer J. Wheler, Stacy L. Moulder,
Siqing Fu, and Razelle Kurzrock
Interactions of Tyrosine Kinase
Inhibitors with Organic Cation
Transporters, OCTs, and Multidrug
and Toxic Compound Extrusion
Proteins, MATEs
Tsuyoshi Minematsu and
Kathleen M. Giacomini
540
Enhanced Anticancer Effect of the
Combination of Cisplatin and TRAIL
in Triple-Negative Breast Tumor
Cells
Antagonism of VEGF by Genetically
Engineered Dendritic Cells Is
Essential to Induce Antitumor
Immunity against Malignant Ascitis
Masahiko Sugiyama, Yoshihiro Kakeji,
Yui Harada, Mitsuho Onimaru,
Kumi Yoshida, Sakura Tanaka, Yasunori Emi,
Masaru Morita, Yosuke Morodomi,
Mamoru Hasegawa, Yoshihiko Maehara, and
Yoshikazu Yonemitsu
ABOUT THE COVER
VEGF and placental growth factor promote angiogenesis in developing
tumors. A novel fusion protein sFLT01 neutralized VEGF and PlGF, and
inhibited tumor growth and blood vessel development in preclinical
tumor models. Using immunofluorescence, it was found that sFLT01
localized to vascular areas in human A673 Ewing’s sarcoma tumors.
VEGFR2 protein was also detected throughout the tumor microenvironment. For details, see article by Bagley and colleagues on page
404.
iv
Molecular Cancer Therapeutics
Downloaded from mct.aacrjournals.org on June 15, 2017. © 2011 American Association for Cancer Research.
10 (3)
Mol Cancer Ther 2011;10:373-565.
Updated version
E-mail alerts
Reprints and
Subscriptions
Permissions
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/10/3
Sign up to receive free email-alerts related to this article or journal.
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at
[email protected].
To request permission to re-use all or part of this article, contact the AACR Publications Department at
[email protected].
Downloaded from mct.aacrjournals.org on June 15, 2017. © 2011 American Association for Cancer Research.